Scil Proteins, a German private biotech company specialising in the research, development and production of recombinant proteins, has appointed Ulrich Haupts as its new chief scientific officer. As of 1 October, he will replace Arnd Steuernagel.
Haupts was previously director of protein optimisation at Bayer Healthcare, a position he has held for the last three years. Prior to that, he spent seven years at Direvo Biotech (which was subsequently acquired by Bayer Schering Pharma in 2008) as department head of assay development and later, as vp of r&d biopharmaceuticals.
Dr Haupts also worked for three years at SmithKline Beecham UK in the New Assay Technology group.
Scil Proteins appoints chief scientific officer
Ulrich Haupts joins the biotech firm from Bayer Healthcare
You may also like
Research & Development
Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases
The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases